loader

PharmaTher Holdings Ltd Com

CNSX:PHRM
PHRRF
1 min read

PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505 NDA Filings

CSE Bulletin: MOC Eligibility Update

PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments

PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments

PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative

PharmaTher Provides Corporate Update Following FDA Approval of Ketamine )

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

Latest News

More News

Latest News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES